| Serial Number | 98850043 |
| Word Mark | CAPSTANTX |
| Filing Date | Tuesday, November 12, 2024 |
| Status | 665 - NOTICE OF UNRESPONSIVE AMENDMENT - COUNTED |
| Status Date | Friday, December 5, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Description of Mark | The mark consists of a curving unbroken line that crosses over itself suggesting a stylized letter "c" adjacent to the word "capstantx". |
| Goods and Services | Pharmaceuticals; pharmaceutical preparations; pharmaceutical substances; therapeutics; therapeutic agents; biopharmaceuticals; medicines; drugs; vaccines; in vivo cell therapies; cells for medical or clinical use; stem cells for medical purposes; cells for medical use; genetically engineered cells; systems to express therapeutic proteins in vivo; gene therapy products; gene therapy preparations; gene therapy products, namely, genetically engineered cells for transplant purposes; in vivo nucleic acid, DNA, RNA, and mRNA technologies; targeted in vivo RNA technologies; lipid nanoparticles for medicinal use; binding moiety decorated lipid nanoparticles for medicinal use; lipid nanoparticles for durable cell reprogramming or cell engineering; binding moiety decorated lipid nanoparticles for durable cell reprogramming or cell engineering; targeted lipid nanoparticles for medicinal use; targeted lipid nanoparticles for durable cell reprogramming or cell engineering; targeted lipid nanoparticles for transient cell reprogramming or cell engineering; cell engineering platforms; cell engineering platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells; in vivo cell engineering platforms; transient in vivo cell engineering platforms for durable gene therapy; technology platforms for transfection, namely, binding moiety decorated lipid nanoparticles for genetic engineering; reagents for transfection; reagents for transfection in vivo; reagents for transfection, namely, binding moiety decorated lipid nanoparticles; technology platforms for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; technology platforms for delivery of a nucleic acid payload; technology platforms for delivery of a negatively charged payload; biologics delivery systems; biologics delivery platforms; reagents for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; cell engineering platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, mRNA, and antibodies or antigen binding portions thereof; biological technology platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, nucleic acid, DNA, RNA, mRNA, and antibodies or antigen binding portions thereof, for the treatment and prevention of treatment of human diseases, disorders and conditions; chemical reagents for medical uses; clinical medical reagents; reagents for medical use; biological reagents for medical use; binding moiety decorated lipid nanoparticles |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, November 12, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | CAPSTAN THERAPEUTICS, INC. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | North Chicago, IL 60064 |
| Event Date | Event Description |
| Tuesday, November 12, 2024 | NEW APPLICATION ENTERED |
| Tuesday, May 6, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, May 6, 2025 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Thursday, May 8, 2025 | ASSIGNED TO EXAMINER |
| Thursday, May 22, 2025 | NON-FINAL ACTION WRITTEN |
| Thursday, May 22, 2025 | NON-FINAL ACTION E-MAILED |
| Thursday, May 22, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, August 20, 2025 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Wednesday, August 20, 2025 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Friday, November 7, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, November 7, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, November 7, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, November 6, 2025 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Thursday, November 6, 2025 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Thursday, November 6, 2025 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Thursday, November 6, 2025 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Thursday, November 6, 2025 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Thursday, November 6, 2025 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Friday, December 5, 2025 | REPORT UNRESPONSIVE AMENDMENT - COMPLETED |